Anavex Life Sciences, a leading pharmaceutical company, has recently announced promising results from
a long-term extension study of their investigational therapy, Anavex 2-73. This
therapy has shown significant reduction in symptom severity among Parkinson’s
disease patients with dementia.
The Phase 2 trial, known as ANAVEX 2-73-PDD-001, included 132 adults with Parkinson’s disease
dementia and tested the efficacy of Anavex 2-73 against a placebo. The study
lasted approximately 3.5 months and indicated that patients receiving Anavex 2-73 once
daily experienced improvements in memory and cognitive skills. Additionally,
the therapy demonstrated clinically meaningful reductions in the severity and
daily impact of both motor and nonmotor symptoms, as evaluated by the Movement
Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).
Following the completion of the Phase 2 trial, participants were given the option to enroll
in an open-label extension study, called ANAVEX 2-73-PDD-EP-001. During this
study, all participants received daily treatment with Anavex 2-73 for almost a
year. Interestingly, there was a noticeable decline in symptom severity during
the period between the end of the Phase 2 trial and the start of the extension
study, when patients were not receiving Anavex 2-73.
However, once participants resumed treatment with Anavex 2-73 in the extension study,
improvements were observed. The median total MDS-UPDRS score at 48 weeks was
similar to the score reported at the end of the Phase 2 trial, before the drug
holiday. This suggests that Anavex 2-73 has the potential to slow and even reverse the life-altering symptoms of
Parkinson’s disease.
Furthermore, the long-term use of Anavex 2-73 was found to be generally safe and well-tolerated,
with no major adverse effects reported. These positive findings have prompted
Anavex Life Sciences to plan a Phase 3 trial to further evaluate the efficacy of
Anavex 2-73 in Parkinson’s disease patients. The results of this trial will
support the filing of regulatory applications for the therapy’s approval.
In conclusion, the long-term benefits of Anavex 2-73 in reducing symptom severity in Parkinson’s
disease patients are highly promising. The results from the extension study
provide hope for those living with this progressive neurodegenerative disorder.
With further research and clinical trials, Anavex 2-73 may offer a much-needed
treatment option for individuals affected by Parkinson’s disease. Anavex Life
Sciences continues to be at the forefront of innovative pharmaceutical
development, bringing new hope to patients worldwide. Follow this page on Twitter, to learn more.
More about Anavex on https://finance.yahoo.com/quote/AVXL/